728 related articles for article (PubMed ID: 17417080)
1. Doping-control analysis of the 5alpha-reductase inhibitor finasteride: determination of its influence on urinary steroid profiles and detection of its major urinary metabolite.
Thevis M; Geyer H; Mareck U; Flenker U; Schänzer W
Ther Drug Monit; 2007 Apr; 29(2):236-47. PubMed ID: 17417080
[TBL] [Abstract][Full Text] [Related]
2. Enzyme-linked immunosorbent assays for doping control of 5alpha-reductase inhibitors finasteride and dutasteride.
Brun EM; Torres A; Ventura R; Puchades R; Maquieira A
Anal Chim Acta; 2010 Jun; 671(1-2):70-9. PubMed ID: 20541645
[TBL] [Abstract][Full Text] [Related]
3. Factors influencing the steroid profile in doping control analysis.
Mareck U; Geyer H; Opfermann G; Thevis M; Schänzer W
J Mass Spectrom; 2008 Jul; 43(7):877-91. PubMed ID: 18570179
[TBL] [Abstract][Full Text] [Related]
4. Searching for new markers of endogenous steroid administration in athletes: "looking outside the metabolic box".
Cawley AT; Hine ER; Trout GJ; George AV; Kazlauskas R
Forensic Sci Int; 2004 Jul; 143(2-3):103-14. PubMed ID: 15240029
[TBL] [Abstract][Full Text] [Related]
5. Profiling of urinary steroids by gas chromatography-mass spectrometry detection and confirmation of androstenedione administration using isotope ratio mass spectrometry.
Wang J; Wu M; Liu X; Xu Y
Steroids; 2011 Dec; 76(14):1560-5. PubMed ID: 21945895
[TBL] [Abstract][Full Text] [Related]
6. Metabolism of 4-hydroxyandrostenedione and 4-hydroxytestosterone: Mass spectrometric identification of urinary metabolites.
Kohler M; Parr MK; Opfermann G; Thevis M; Schlörer N; Marner FJ; Schänzer W
Steroids; 2007 Mar; 72(3):278-86. PubMed ID: 17207827
[TBL] [Abstract][Full Text] [Related]
7. Influences of musk administration on the doping test.
He Y; Wang J; Liu X; Xu Y; He Z
Steroids; 2013 Nov; 78(11):1047-52. PubMed ID: 23891647
[TBL] [Abstract][Full Text] [Related]
8. 5α-reductase inhibitors: Evaluation of their potential confounding effect on GC-C-IRMS doping analysis.
Iannella L; Colamonici C; Curcio D; Botrè F; de la Torre X
Drug Test Anal; 2021 Nov; 13(11-12):1852-1861. PubMed ID: 34318592
[TBL] [Abstract][Full Text] [Related]
9. Effects of propyphenazone and other non-steroidal anti-inflammatory agents on the synthetic and endogenous androgenic anabolic steroids urinary excretion and/or instrumental detection.
Mazzarino M; Braganò MC; Donati F; de la Torre X; Botrè F
Anal Chim Acta; 2010 Jan; 657(1):60-8. PubMed ID: 19951758
[TBL] [Abstract][Full Text] [Related]
10. Determination of the deuterium/hydrogen ratio of endogenous urinary steroids for doping control purposes.
Piper T; Thevis M; Flenker U; Schänzer W
Rapid Commun Mass Spectrom; 2009 Jul; 23(13):1917-26. PubMed ID: 19462405
[TBL] [Abstract][Full Text] [Related]
11. Determination of 13C/12C ratios of endogenous urinary steroids: method validation, reference population and application to doping control purposes.
Piper T; Mareck U; Geyer H; Flenker U; Thevis M; Platen P; Schänzer W
Rapid Commun Mass Spectrom; 2008 Jul; 22(14):2161-75. PubMed ID: 18536069
[TBL] [Abstract][Full Text] [Related]
12. Relevance of the selective oestrogen receptor modulators tamoxifen, toremifene and clomiphene in doping field: endogenous steroids urinary profile after multiple oral doses.
Mazzarino M; Braganò MC; de la Torre X; Molaioni F; Botrè F
Steroids; 2011 Nov; 76(12):1400-6. PubMed ID: 21745489
[TBL] [Abstract][Full Text] [Related]
13. Mass spectrometric identification and characterization of a new long-term metabolite of metandienone in human urine.
Schänzer W; Geyer H; Fusshöller G; Halatcheva N; Kohler M; Parr MK; Guddat S; Thomas A; Thevis M
Rapid Commun Mass Spectrom; 2006; 20(15):2252-8. PubMed ID: 16804957
[TBL] [Abstract][Full Text] [Related]
14. New 5alpha-reductase inhibitors: in vitro and in vivo effects.
Pérez-Ornelas V; Cabeza M; Bratoeff E; Heuze I; Sánchez M; Ramírez E; Naranjo-Rodríguez E
Steroids; 2005 Mar; 70(3):217-24. PubMed ID: 15763601
[TBL] [Abstract][Full Text] [Related]
15. Drug testing data from the 2007 Pan American Games: delta13C values of urinary androsterone, etiocholanolone and androstanediols determined by GC/C/IRMS.
Aguilera R; Chapman TE; Pereira H; Oliveira GC; Illanes RP; Fernandes TF; Azevedo DA; Neto FA
J Steroid Biochem Mol Biol; 2009 Jul; 115(3-5):107-14. PubMed ID: 19428237
[TBL] [Abstract][Full Text] [Related]
16. Determination of the origin of urinary norandrosterone traces by gas chromatography combustion isotope ratio mass spectrometry.
Hebestreit M; Flenker U; Fusshöller G; Geyer H; Güntner U; Mareck U; Piper T; Thevis M; Ayotte C; Schänzer W
Analyst; 2006 Sep; 131(9):1021-6. PubMed ID: 17047802
[TBL] [Abstract][Full Text] [Related]
17. Metabolic studies of mesterolone in horses.
Ho EN; Leung DK; Leung GN; Wan TS; Wong HN; Xu X; Yeung JH
Anal Chim Acta; 2007 Jul; 596(1):149-55. PubMed ID: 17616252
[TBL] [Abstract][Full Text] [Related]
18. Metabolism of androsta-1,4,6-triene-3,17-dione and detection by gas chromatography/mass spectrometry in doping control.
Parr MK; Fusshöller G; Schlörer N; Opfermann G; Piper T; Rodchenkov G; Schänzer W
Rapid Commun Mass Spectrom; 2009 Jan; 23(2):207-18. PubMed ID: 19089863
[TBL] [Abstract][Full Text] [Related]
19. Finasteride, a 5alpha-reductase inhibitor, blocks the anticonvulsant activity of progesterone in mice.
Kokate TG; Banks MK; Magee T; Yamaguchi S; Rogawski MA
J Pharmacol Exp Ther; 1999 Feb; 288(2):679-84. PubMed ID: 9918575
[TBL] [Abstract][Full Text] [Related]
20. Doping in sport--1. Excretion of 19-norandrosterone by healthy women, including those using contraceptives containing norethisterone.
Walker CJ; Cowan DA; James VH; Lau JC; Kicman AT
Steroids; 2009 Mar; 74(3):329-34. PubMed ID: 19010339
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
